Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Главный автор: | Paul, Pulock |
---|---|
Другие авторы: | Azam,Faruque |
Формат: | Диссертация |
Язык: | English |
Опубликовано: |
Brac University
2024
|
Предметы: | |
Online-ссылка: | http://hdl.handle.net/10361/23954 |
Схожие документы
-
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
по: Rahman, Tasnim
Опубликовано: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
по: Hoque, Ismoth Ara
Опубликовано: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
по: Karim, Samia Binte
Опубликовано: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
по: Flora, Sanzida Alam
Опубликовано: (2024) -
A review on targeted therapies for lung cancer
по: Ashraf, Anushey
Опубликовано: (2023)